Also, keep in mind that comparing %RRRs from one trial to another isn't exactly an apples to apples comparison. One must keep in mind the absolute risk of the patient population and the absolute risk reduction (ARR), which is used to calculate the number needed to treat (NNT) to prevent an event. If apabetalone elicits a %RRR in the ballpark of 30% in the high-risk diabetic, low-HDL, recent ACS BETonMACE population, this will achieve an amazing (unprecedented?) ARR and NNT for 3-point MACE reduction due to the high absolute risk of the patients. The ARR and NNTs in other trials acheiving %RRRs for 3-point MACE in the 15-30% range won't be nearly as impressive as BETonMACE (assuming BETonMACE succeeds with a ~30% RRR) because of the very high absolute risk of BETonMACE patients. Most other trials are comprised of lower risk patients.

BearDownAZ